27 min listen
Advancing an Antibody to Prevent and Treat Cytokine Storms in COVID-19
FromThe Bio Report
ratings:
Length:
19 minutes
Released:
Dec 10, 2020
Format:
Podcast episode
Description
There are many approved or experimental therapies in development for a range of indications that, because of their mechanisms of action, have been pursued as potential therapies to treat patients with COVID-19. One of the most advanced candidates in this category is lenzilumab, an experimental monoclonal antibody that’s in development for certain cancers and other conditions. The antibody has the potential to neutralize a cytokine known as GM-CSF, which can trigger a severe immune reaction and cause hyperinflammation as a result of a cytokine storm. It is this immune response that underlies the most serious cases of COVID-19 virus. We spoke to Cameron Durrant, chairman and CEO of Humanigen, about lenzilumab, how it was recognized as a potential treatment for COVID-19, and the path forward for the therapy.
Released:
Dec 10, 2020
Format:
Podcast episode
Titles in the series (100)
Will Increased FDA Regulation of Diagnostics Speed or Slow Development of Personalized Medicine: The U.S. Food and Drug Administration is moving to expand its regulatory domain by adding oversight of certain diagnostics it does not regulate today. The agency says thousands of these test are used daily to guide treatment decisions and diagnose di... by The Bio Report